Prescribing information (external link)
SCEMBLIX®▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation.1
SCEMBLIX®▼ (asciminib). A targeted approach against CML1
For many patients, treatment priorities extend beyond disease control when receiving their 2nd or 3rd TKI2
Without consistent monitoring of molecular responses and treatment-related AEs, patients requiring a treatment switch may not be identified, potentially leading to suboptimal outcomes3–5
The first and only inhibitor Specifically Targeting the ABL1 Myristoyl Pocket (STAMP)6,7
SCEMBLIX demonstrated superior efficacy vs bosutinib as early as Week 24 (MMR: 25.5% vs 13.2%, p=0.029)7
SCEMBLIX demonstrated superior efficacy vs bosutinib, a 2G TKI, at Week 24 (MMR: 25.5% vs 13.2%, p=0.029) and was observed to demonstrate a more generally tolerable safety profile1,7
The most common AEs of any grade (incidence ≥20%) in patients receiving SCEMBLIX were musculoskeletal pain (38.8%), upper respiratory tract infections (29.5%), fatigue (28.9%), thrombocytopenia (28.1%), headache (26.4%), arthralgia (24.4%), increased pancreatic enzymes (23%), diarrhoea (22.5%), abdominal pain (22.2%), rash (21.6%), hypertension (20.8%) and nausea (20.8%). For further information, please refer to the Summary of Product Characteristics.
AE, adverse event; CML, chronic myeloid leukaemia; CP, chronic phase; MMR, major molecular response; MoA, mechanism of action; Ph+ CML, Philadelphia chromosome-positive chronic myeloid leukaemia; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitor.
References
SCEMBLIX (asciminib) Summary of Product Characteristics.
Lang F, et al. Haematologica 2025; doi: 10.3324/haematol.2025.287772.
Chen H, et al. Oncol Ther 2024;12:131–145.
Goldberg SL, et al. Curr Med Res Opin 2013;29:1075–1082.
DeAngelo DJ. Blood Cancer J 2012;2:e9.
Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
Réa D, et al. Blood 2021;138(21):2031–2041.
UK | January 2026 | FA-11572842
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
